ELVN CEO Form 4 shows 12,500-share sale, 890,392 shares held

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. (ELVN) President, CEO and Director reported a sale of company stock in a Form 4 filing. On 11/17/2025, the reporting person sold 12,500 shares of common stock at a weighted average price of $21.8191, with individual trade prices ranging from $21.37 to $22.3537. The transaction is marked as a sale and was executed under a Rule 10b5-1 trading plan that was adopted on November 15, 2024, which is a pre-arranged plan designed to systematically sell shares over time. After this transaction, the reporting person indirectly beneficially owns 890,392 shares, held by The Kintz & Egan Trust Dated March 30, 2019, where the reporting person serves as trustee.

Insider Trade Summary

Net Seller: 12,500 shares ($272,739)

Net Sell 1 txn

Insider Kintz Samuel

Role PRESIDENT AND CEO

Sold 12,500 shs ($273K)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,500	$21.8191	$273K

Holdings After Transaction: Common Stock — 890,392 shares (Indirect, See footnote)

Footnotes (1)

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. This transaction was executed in multiple trades at prices ranging from $21.37 to $22.3537. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kintz Samuel

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S(1)		12,500	D	$21.8191(2)	890,392	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

2. This transaction was executed in multiple trades at prices ranging from $21.37 to $22.3537. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

	/s/ Ben Hohl, by power of attorney	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Enliven Therapeutics (ELVN) report?

The President, CEO and Director of Enliven Therapeutics (ELVN) reported selling 12,500 shares of common stock on 11/17/2025 in an open market transaction.

At what prices were the ELVN shares sold in this Form 4 filing?

The ELVN shares were sold at prices ranging from $21.37 to $22.3537, with a weighted average sale price of $21.8191 for the 12,500 shares.

Is the Enliven Therapeutics (ELVN) insider sale under a Rule 10b5-1 plan?

Yes. The filing states the sales were made under a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

How many Enliven Therapeutics (ELVN) shares does the insider still beneficially own?

Following the reported transaction, the insider beneficially owns 890,392 shares of ELVN common stock indirectly.

How are the remaining ELVN shares held by the reporting person?

The remaining 890,392 shares are held of record by The Kintz & Egan Trust Dated March 30, 2019, for which the reporting person serves as trustee.

What roles does the reporting person hold at Enliven Therapeutics (ELVN)?

The reporting person is a Director and serves as President and CEO of Enliven Therapeutics, Inc.